Efficacy of Iodine Complex Against COVID-19 Patients (I-COVID-PK)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04473261 |
Recruitment Status :
Recruiting
First Posted : July 16, 2020
Last Update Posted : July 7, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Covid19 SARS-CoV-2 Corona Virus Infection | Drug: Iodine Complex Drug: Placebo Drug: Idoine Complex | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Randomized, controlled, multi-armed, close-label, interventional study designed |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | empty capsule will be given as a placebo |
Primary Purpose: | Treatment |
Official Title: | Efficacy of Iodine Complex in Mild to Moderate COVID-19 Patients |
Actual Study Start Date : | July 14, 2020 |
Estimated Primary Completion Date : | August 15, 2021 |
Estimated Study Completion Date : | October 15, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Iodine Complex (Capsule form)
Iodine Complex) capsule (200mg) will be given three times a day
|
Drug: Iodine Complex
Iodine Complex capsule (200mg) will be given three times a day |
Experimental: Iodine Complex (Syrup form)
Iodine Complex syrup form (40ml) will be given three times a day
|
Drug: Iodine Complex
Iodine Complex syrup form (40ml) will be given three times a day |
Placebo Comparator: Standard Care Alone
Placebo as empty capsule. Treatment will be given for all 4 arms will be receiving standard care as per version 3.0 of clinical management guidelines for COVID-19 established by the Ministry of National Health Services of Pakistan COVID-19 guidelines of the study setting.
|
Drug: Placebo
Empty capsule will be given as placebo
Other Name: capsule |
Experimental: Iodine Complex (Nasal Spray)
Iodine complex throat spray of 2 puffs three times a day.
|
Drug: Idoine Complex
Iodine Complex spray form 2 puffs will be given three times a day |
- qRT-PCR [ Time Frame: 14 days ]Time taken for viral load clearance
- HRCT chest [ Time Frame: 14 days ]Time taken for radiological improvement
- Severity of Symptoms [ Time Frame: 14 days ]Time taken for symptomatic response in patients

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Positive PCR with mild to moderate disease
Exclusion Criteria:
- Allergic to iodine
- Any co-morbidity other than hypertension and dietetics

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04473261
Contact: Sohaib Ashraf, MBBS | +923334474523 | sohaib-ashraf@outlook.com | |
Contact: Shoaib Ashraf, PhD | +16177949579 | sashraf@mgh.harvard.edu |
Pakistan | |
Shaikh Zayed Hospital | Recruiting |
Lahore, Pakistan, 54600 | |
Contact: Sohaib Ashraf, MBBS +923334474523 sohaib@skzmdc.edu.pk | |
Contact: Muhammad Ahmad Imran, MBBS +923338110708 ahmad.ammy93@gmail.com | |
Principal Investigator: Muhammad Ahmad Imran, MBBS | |
Sub-Investigator: Uzma Nasim, FCPS |
Study Chair: | Muhammad Ashraf, PhD | University of Veterinary & Animal Sciences, Pakistan | |
Study Director: | Shoaib Ashraf, PhD | Harvard University, Massachusetts General Hospital, Boston, USA | |
Principal Investigator: | Moneeb Ashraf, MBBS | Mayo Hospital, Pakistan | |
Principal Investigator: | Sohaib Ashraf, MBBS | Shaikh Zayed Medical Complex, Pakistan |
Responsible Party: | Sohaib Ashraf, Post-Graduate Resident Cardiology, Sheikh Zayed Federal Postgraduate Medical Institute |
ClinicalTrials.gov Identifier: | NCT04473261 |
Other Study ID Numbers: |
SZMC/IRB/Internal/216/2020 |
First Posted: | July 16, 2020 Key Record Dates |
Last Update Posted: | July 7, 2021 |
Last Verified: | July 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
SARS-Cov-2 COVID-19 Coronavirus Iodine Complex |
COVID-19 Coronavirus Infections Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronaviridae Infections Nidovirales Infections RNA Virus Infections |
Lung Diseases Respiratory Tract Diseases Iodine Cadexomer iodine Anti-Infective Agents, Local Anti-Infective Agents Trace Elements Micronutrients Physiological Effects of Drugs |